Exagen Inc. achieves its 1,000,000th AVISE CTD test, enhancing autoimmune disease diagnosis and patient care. Quiver AI Summary Exagen Inc. has reached a major milestone by completing its 1,000 ...

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...

Since launching AVISE CTD in 2012, Exagen has produced an extensive body of peer-reviewed literature supporting the test’s clinical validity and utility.

The European Alliance of Associations for Rheumatology – has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...

The AVISE CTD test that rheumatologists have come to know and trust is composed of multiple biomarker assays that assist in the clinical diagnosis of the most common CTDs, which included: ...

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s dedication to supporting patients and clinicians managing ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month ...

What is the AVISE® CTD? AVISE® CTD is a blood test that can help doctors diagnose lupus and other autoimmune diseases — like rheumatoid arthritis, Sjögren's syndrome, or scleroderma. The test may be ...

Q2 2025 Highlights: Growth and Expansion, but Persistent Losses Revenue (GAAP) climbed 14.2% from the prior year to $17.2 million, driven by the AVISE CTD test.